Identification of Novel Cyclobutane-Based Derivatives as Potent Acetyl-CoA Carboxylase Allosteric Inhibitors for Nonalcoholic Steatohepatitis Drug Discovery

Identification of Novel Cyclobutane-Based Derivatives as Potent Acetyl-CoA Carboxylase Allosteric Inhibitors for Nonalcoholic Steatohepatitis Drug Discovery

Nonalcoholic steatohepatitis (NASH) has become a leading cause of liver fibrosis and hepatocellular carcinoma; however, there are no efficient drugs for NASH therapy. Acetyl-CoA carboxylase (ACC) is a crucial enzyme regulating lipid metabolism that is considered as a potential target for NASH treatm...

Full description

Saved in:
Bibliographic Details
Main Author: Yazhou Wang (1508368) (author)
Other Authors: Hai Wang (310051) (author), Qingqing Li (1505614) (author), Ying Zhang (40767) (author), Rupeng Dai (7817822) (author), Jun Wu (4002) (author), Yanan Zhang (1322391) (author), Xiaomeng Zhang (182897) (author), Liwen Zhao (2886926) (author), Jian Liu (33711) (author)
Published: 2025
Subjects:
Biochemistry
Medicine
Genetics
Molecular Biology
Pharmacology
Biotechnology
Infectious Diseases
Virology
Biological Sciences not elsewhere classified
Chemical Sciences not elsewhere classified
Information Systems not elsewhere classified
potent therapeutic effect
several hotspot residues
b1 </ b
hotspot residues
several cyclobutane
vivo </
vitro </
protein families
promising candidate
potential target
potent acetyl
novel cyclobutane
leading cause
initially identified
important source
highly variable
higher distribution
hepatocellular carcinoma
gbsa calculation
efficient drugs
drug candidates
coa carboxylase
biologically evaluated
based derivatives
allosteric inhibitors
alanine mutation
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items